Primity Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Primity Bio, Inc. - overview
Established
2010
Location
Fremont, CA, US
Primary Industry
Biotechnology
About
Primity Bio, Inc. is a biotechnology company focused on advancing precision medicine through innovative therapeutic development solutions and contract research services. Primity Bio, Inc. specializes in precision medicine and therapeutic development solutions.
Founded in 2010, the company is headquartered in Fremont, US. In August 2018, Primity Bio was acquired by Caprion Proteomics Inc. , a portfolio company of GHO Capital. The financial terms of the acquisition were not disclosed.
Primity Bio operates as a Contract Research Organization (CRO) offering precision medicine services that cover a wide range of scientific capabilities, including bioinformatics, histopathology, immune monitoring, and genomic services. Their expertise in integrated sample management ensures efficient handling of specialty samples. Primity's laboratory in Jining, China, is CAP-accredited and provides services to clients in oncology programs, offering flow cytometry and immunoassays to biopharmaceutical companies and research institutions across North America, Europe, and Asia. Primity Bio generates revenue through direct service contracts and partnerships with biopharmaceutical firms and research centers.
Their financial transactions involve contract services for specific assays and analyses that support therapeutic development. Services such as Companion Diagnostic (CDx) development and mass spectrometry-based biomarker analysis are charged on a project basis, reflecting the complexity and customization required for high-end scientific capabilities. Primity Bio plans to leverage its recent acquisition to enhance its service offerings and expand into new markets. The company is focusing on developing new products that are aligned with the evolving needs of precision medicine and anticipates launching these initiatives in the coming fiscal year.
The funding from the acquisition will be utilized to support these developments and expand their geographic reach, particularly targeting new clients in emerging markets across Asia and Europe. The most recent deal occurred on August 21, 2018, when Caprion Proteomics acquired Primity Bio, Inc.
Current Investors
Caprion Biosciences Inc.
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Diagnostic, Medical & Imaging Laboratories, Pharmaceutical Research & Development
Website
http://primitybio.com/
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Primity Bio, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Primity Bio, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.